A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SELECT
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 27 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.